학술논문

Randomized controlled trial of remote ischemic preconditioning in children having cardiac surgery
Document Type
Report
Source
Journal of Cardiothoracic Surgery. January 3, 2024, Vol. 19 Issue 1
Subject
Care and treatment
Congenital heart defects -- Care and treatment
Heart diseases -- Care and treatment
Child health
Troponin
Pediatric cardiology
Natriuretic peptides
Genetic disorders -- Care and treatment
Coronary artery bypass
Congenital heart disease -- Care and treatment
Children -- Health aspects
Language
English
ISSN
1749-8090
Abstract
Author(s): Yuk M. Law[sup.1,2], Christine Hsu[sup.3], Sangeeta R. Hingorani[sup.1,2], Michael Richards[sup.1,2], David M. McMullan[sup.1,2], Howard Jefferies[sup.1,2], Jonathan Himmelfarb[sup.2] and Ronit Katz[sup.2] Introduction Children undergoing cardiovascular surgery requiring cardiopulmonary bypass are [...]
Background Children undergoing cardiac surgery are at risk for acute kidney injury (AKI) and cardiac dysfunction. Opportunity exists in protecting end organ function with remote ischemic preconditioning. We hypothesize this intervention lessens kidney and myocardial injury. Methods We conducted a randomized, double blind, placebo controlled trial of remote ischemic preconditioning in children undergoing cardiac surgery. Pre-specified end points are change in creatinine, estimated glomerular filtration rate, development of AKI, B-type natriuretic peptide and troponin I at 6, 12, 24, 48, 72 h post separation from bypass. Results There were 45 in the treatment and 39 patients in the control group, median age of 3.5 and 3.8 years, respectively. There were no differences between groups in creatinine, cystatin C, eGFR at each time point. There was a trend for a larger rate of decrease, especially for cystatin C (p = 0.042) in the treatment group but the magnitude was small. AKI was observed in 21 (54%) of control and 16 (36%) of treatment group (p = 0.094). Adjusting for baseline creatinine, the odds ratio for AKI in treatment versus control was 0.31 (p = 0.037); adjusting for clinical characteristics, the odds ratio was 0.34 (p = 0.056). There were no differences in natriuretic peptide or troponin levels between groups. All secondary end points of clinical outcomes were not different. Conclusions There is suggestion of RIPC delivering some kidney protection in an at-risk pediatric population. Larger, higher risk population studies will be required to determine its efficacy. Trial registration and date: Clinicaltrials.gov NCT01260259; 2021. Keywords: Congenital heart disease, Cardiothoracic surgery, Children, Remote ischemic preconditioning, Kidney injury